Oppenheimer reaffirmed their outperform rating on shares of Achieve Life Sciences (NASDAQ:ACHV – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $11.00 target price on the biopharmaceutical company’s stock.
Separately, Jonestrading initiated coverage on shares of Achieve Life Sciences in a report on Wednesday, April 17th. They issued a buy rating and a $20.00 price objective for the company.
Get Our Latest Analysis on Achieve Life Sciences
Achieve Life Sciences Price Performance
Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). During the same period last year, the business earned ($0.43) EPS. As a group, equities analysts expect that Achieve Life Sciences will post -1.05 EPS for the current fiscal year.
Institutional Investors Weigh In On Achieve Life Sciences
Several hedge funds and other institutional investors have recently bought and sold shares of ACHV. Propel Bio Management LLC acquired a new position in shares of Achieve Life Sciences in the 1st quarter worth approximately $11,149,000. CVI Holdings LLC purchased a new position in shares of Achieve Life Sciences in the first quarter worth approximately $2,578,000. Vanguard Group Inc. raised its stake in Achieve Life Sciences by 56.6% during the 1st quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company’s stock valued at $4,311,000 after purchasing an additional 342,731 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at about $482,000. Finally, Rhumbline Advisers purchased a new position in Achieve Life Sciences during the second quarter valued at approximately $197,000. 33.52% of the stock is currently owned by institutional investors.
About Achieve Life Sciences
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
- Five stocks we like better than Achieve Life Sciences
- Insider Trades May Not Tell You What You Think
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- How to Calculate Inflation Rate
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.